Flight Centre posts $25.7B FY26 transaction value
Flight Centre (ASX:FLT) delivered a record total transaction value of $25.7 billion for the 2026 fiscal year.
Flight Centre (ASX:FLT) delivered a record total transaction value of $25.7 billion for the 2026 fiscal year.
Perseus Mining (ASX:PRU) reported a 14% increase in annual net profit after tax to $480.5 million.
Steadfast Group (ASX:SDF) reported a full-year statutory net profit after tax of $269.1 million for FY26.
The combined BHP Ports Unions have submitted a counterproposal for a new wage agreement covering 450 Port Hedland workers.
Intuit (NASDAQ:INTU) reported fiscal 2026 revenue of $21.4 billion, up 14% year over year, with higher revenue across its Global Business Solutions, Online Ecosystem, and Consumer businesses.
SpaceX (NASDAQ:SPCX) announced plans to launch its first AI-powered satellite systems in Q4 2027, with the company developing orbital computing infrastructure using Nvidia (NASDAQ:NVDA) technology.
Formula Systems (NASDAQ:FORTY) reported second-quarter 2026 revenue of $782.4 million, a record level and a 29.8% increase year over year, with higher operating income and shareholder earnings from continuing operations.
Huntsman (NYSE:HUN) and Olin (NYSE:OLN) announced that shareholders of both companies approved proposals required to complete their all-stock merger of equals, which will create OlinHuntsman Corporation.
BeOne Medicines (NASDAQ:ONC) received U.S. FDA approval for TEVIMBRA (tislelizumab) combined with ZIIHERA (zanidatamab) and chemotherapy as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
Jazz Pharmaceuticals (NASDAQ:JAZZ) received U.S. Food and Drug Administration approval for two Ziihera (zanidatamab-hrii) treatment regimens for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.
GET YOUR GRAFA EDGE NOW
Sign up free to unlock this feature
We'll switch on a 30-day Edge trial as a welcome gift